Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice

Prostaglandins and Other Lipid Mediators

Volumn 84, Issue 1-2, 2007, Pages 34-42

  Cao, Richard Yang ^a   Adams, Michael A ^a   Habenicht, Andreas J ^b   Funk, Colin D ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

5 Lipoxygenase; Aneurysm; Inflammation; Leukotriene; Mouse model

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ANGIOTENSIN II; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; INCIDENCE; MOUSE; NONHUMAN; PATHOGENESIS;

ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; ARACHIDONATE 5-LIPOXYGENASE; BLOOD PRESSURE; INDOLES; INFLAMMATION; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, GENETIC; QUINOLINES; TIME FACTORS;

EID: 34447538179     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.03.005     Document Type: Article

References (25)

1. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
2. Drazen J.M. Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 158 (1998) S193-S200
3. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discovery 4 (2005) 664-672
4. Lotzer K., Funk C.D., and Habenicht A.J. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta 1736 (2005) 30-37
5. Spanbroek R., Grabner R., Lotzer K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 100 (2003) 1238-1243
6. Qiu H., Gabrielsen A., Agardh H.E., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 103 (2006) 8161-8166
7. Dwyer J.H., Allayee H., Dwyer K.M., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350 (2004) 29-37
8. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
9. Helgadottir A., Gretarsdottir S., St Clair D., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
10. Helgadottir A., Manolescu A., Helgason A., et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 38 (2006) 68-74
11. Zee R.Y., Cheng S., Hegener H.H., Erlich H.A., and Ridker P.M. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37 (2006) 2007-2011
12. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126 [Erratum in: Circ Res 2002;91:e27]
13. Zhao L., Moos M.P., Grabner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10 (2004) 966-973
14. Aiello R.J., Bourassa P.A., Lindsey S., Weng W., Freeman A., and Showell H.J. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22 (2002) 443-449
15. Subbarao K., Jala V.R., Mathis S., et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 24 (2004) 369-375
16. Heller E.A., Liu E., Tager A.M., et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 12 (2005) 578-586
17. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 (2000) 1605-1612
18. Daugherty A., Manning M.W., and Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134 (2001) 865-870
19. Lin C., Hsieh Y.K., Matuszewski B.K., et al. An automated sample preparation and high performance liquid chromatographic method for the determination of MK-591, a novel leukotriene biosynthesis inhibitor, in human plasma. J Pharm Biomed Anal 14 (1996) 1601-1608
20. Brideau C., Chan C., Charleson S., et al. Pharmacology of MK-0591 (3-[l-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 70 (1992) 799-807
21. Saraff K., Babamusta F., Cassis L.A., and Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23 (2003) 1621-1626
22. Daugherty A., Rateri D.L., and Cassis L.A. Role of the renin-angiotensin system in the development of abdominal aortic aneurysms in animals and humans. Ann NY Acad Sci 1085 (2006) 82-91
23. Daugherty A., and Cassis L.A. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 24 (2004) 429-434
24. King V.L., Trivedi D.B., Gitlin J.M., and Loftin C.D. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1137-1143
25. Ghazalpour A., Wang X., Lusis A.J., and Mehrabian M. Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics 173 (2006) 943-951